Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 8/20 | 0.72 |
| ▸ | MMP2 | P08253 | 7/20 | 0.72 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | USP5 | P45974 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8364898 | 0.93 | MMP13 (0.72) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8364987 | 0.91 | MMP13 (0.78) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8363040 | 0.86 | MMP13 (0.75) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL5898969 | 0.84 | MMP13 (0.82) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL5898973 | 0.84 | MMP13 (1.00) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8364872 | 0.84 | MMP13 (0.78) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8364812 | 0.82 | MMP13 (0.76) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8365029 | 0.82 | MMP13 (0.70) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8361681 | 0.82 | MMP13 (0.78) | MMP13MMP2FPR2PROKR1MMP12 | |
| SCHEMBL8364691 | 0.81 | MMP13 (0.69) | MMP13MMP2FPR2PROKR1MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115632-B1 | Sulfonyl aryl or heteroaryl hydroxamic acid compounds | G. D. SEARLE & CO. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1406602-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| EP-1406626-A2 | SULPHONYL ARYL HYDROXAMATES AND THEIR USE AS MMP INHIBITORS | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6696449-B2 | CONTROL DEGRADATION OF CONENCTING TISSUE; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-02-24 | — | — | US | disclosed |
| US-6683078-B2 | REDUCING DEGRADATION OF CONNECTIVE TISSUE DUE TO CANCER OR INFLAMMATION | PHARMACIA CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-04-17 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2003007930-A2 | USE OF SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACIDS AND DERIVATIVES THEREOF AS AGGRECANASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| EP-1177173-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2002-02-06 | — | — | EP | disclosed |
| WO-2001085680-A2 | SULFONYL ARYL OR HETEROARYL HYDROXAMIC ACID COMPOUNDS | PHARMACIA CORPORATION (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000069819-A1 | HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073845-A1 | Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors | ARSA, MMP1, MMP3 | MMP13 8/4885MMP2 7/4885FPR2 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.